Evidence map›Paper›PMID 41838460›Full record

ArticleEndocrine-related cancer2026

Adrenocortical carcinoma as a manifestation of Birt-Hogg-Dubé syndrome.

Katherine I Wolf, Jenae Osborne, Antonio M Lerario, Josh N Vo, Oksana Hamidi, Mouhammed Amir Habra, Gary Hammer, Tobias Else

Abstract read
In one paragraph

Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katherine I WolfDepartment of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, Michigan, USA.ORCID 0000-0001-8540-8248
Jenae OsborneDepartment of Internal Medicine, Division of Genetic Medicine, Michigan Medicine, Ann Arbor, Michigan, USA.
Antonio M LerarioDepartment of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, Michigan, USA.
Josh N VoDepartment of Pathology, Michigan Medicine, Ann Arbor, Michigan, USA.
Oksana HamidiDivision of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Mouhammed Amir HabraDepartment of Endocrine Neoplasia & Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gary HammerDepartment of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, Michigan, USA.
Tobias ElseDepartment of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, Michigan, USA.

Funding

TRAINING PROGRAM IN ENDOCRINOLOGY AND METABOLISM.T32DK007245 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RICHARD J. AUCHUS · 1986 to 2026
$7.2M
Exploring Pathophysiology and Treatment Approaches in Mild Autonomous Cortisol SecretionK23DK142038 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Oksana Hamidi · 2025 to 2026
$379k
NIDDK NIH HHS K23 DK142038NIDDK NIH HHS T32 DK007245
6 · The paper itself

Abstract

Birt-Hogg-Dubé syndrome (BHDS) is characterized by fibrofolliculomas, trichodiscomas, renal tumors, lung cysts, and spontaneous pneumothoraces. Other than renal cell carcinoma, no cancers have been confirmed as part of the BHDS tumor spectrum. Here, we set out to uncover if adrenocortical carcinoma (ACC) is associated with BHDS. A retrospective review at a single tertiary care center between 2010 and 2024 was performed using search terms describing the clinical manifestations of BHDS, adrenal tumors, and iterations thereof. The initial review identified 1,010 patients with ACC. Of these patients, 466 were evaluated by a genetic counselor, and 346 underwent genetic testing-seven of which were found to have either characteristic clinical features of BHDS or a confirmed diagnosis. The literature review over the same time period demonstrated five additional cases of malignant adrenal tumors in patients with BHDS. We observed BHDS, confirmed by a pathogenic FLCN variant in 0.7% of all ACC patients, or 1.5% of patients evaluated by a genetic counselor and 2.0% of all patients who underwent genetic testing. Testing for FLCN pathogenic variants should be considered during routine genetic evaluation of patients with ACC, and special attention should be paid to adrenal tumors in BHDS patients during surveillance for renal neoplasms as more than 50% of patients in this series developed metastatic disease.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaBirt-Hogg-Dube SyndromeAdolescentAdultAgedFemaleHumansMaleMiddle AgedProto-Oncogene ProteinsRetrospective StudiesTumor Suppressor ProteinsYoung AdultFLCN protein, humanProto-Oncogene ProteinsTumor Suppressor Proteinsadrenocortical carcinomaBirt–Hogg–Dubégenetic syndromeprevalence

Identifiers

PMID41838460
PMCPMC13182339

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.